← All Camp4 Therapeutics CORP filings

Camp4 Therapeutics CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CAMP
Camp4 Therapeutics CORP
10-K: CAMP4 Therapeutics Reports Increased Losses, Advances SYNGAP1 Program
CAMP4 Therapeutics reported a significant increase in net losses for 2025, reaching $80.4 million, while advancing its lead SYNGAP1 therapeutic and securing new funding and collaborations.
NASDAQ
CAMP
Camp4 Therapeutics CORP
10-K: CAMP4 Therapeutics Reports Full Year 2024 Results, Provides Clinical Trial Update
CAMP4 Therapeutics reports its full year 2024 financial results and provides an update on its clinical and preclinical programs, including the ongoing Phase 1 trial for CMP-CPS-001.